Oxcarbazepine: current status and clinical applications

Bibliography

• DEGEN PH, FLESCH G, CARDOT JM, CZENDLIK C, DIETERLE W: The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharm. Drug Dispos. (1994) 15:519–526.
   PubMed Web of Science ®Google Scholar
• SCHUTZ H, FELDMANN KF, FAIGLE JW, KRIEMLER HP, WINKLER T: The metabolism of 14C-oxcarbazepine in man. Xenobiotica (1986) 16:769–778.
   PubMed Web of Science ®Google Scholar
• •Comprehensive description of the metabolism of oxcarbazepine.
   Google Scholar
• BARUZZI A, ALBANI F, RIVA R: Oxcarbazepine: pharma-cokinetic interactions and their clinical relevance. Epilepsia (1994) 35 (Suppl. 3):S14–S19.
   Google Scholar
• KERANEN T, JOLKKONEN J, KLOSTERSKOV-JENSEN P, MENGE GP: Oxcarbazepine does not interact with cimetidine in healthy volunteers. Acta Neurol Scand. (1992) 85:239–242.
   PubMed Web of Science ®Google Scholar
• MOGENSEN PH, JORGENSEN L, BOAS J et al: Effects ofdextropropoxyphene on the steady-state kinetics of oxcarbazepine and its metabolites. Acta Neurol Scand. (1992) 85:14–17.
   PubMed Web of Science ®Google Scholar
• KERANEN T, JOLKKONEN J, JENSEN PK, MENGE GP, ANDERSSON P: Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol. Scand. (1992) 86:120–123.
   PubMed Web of Science ®Google Scholar
• KRAMER G, TETTENBORN B, FLESCH G: Oxcarbazepine-verapamil drug interaction in healthy volunteers. Epilepsia (1991) 32 (Suppl. 0:70–71.
   Google Scholar
• KERANEN T, MOBIUS HJ, SCHURR-EISINGER S et al.: Effect of oxcarbazepine on hepatic clearance of antipyrine in patients with previously untreated epilepsy. Epilepsia (1995) 36\(Suppl. 3):S161.
   Google Scholar
• LARKIN JG, MCKEE PJ, FORREST G et al.: Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br. J. Clin. Pharmacol (1991) 31:65–71.
   PubMed Web of Science ®Google Scholar
• ISOJARVI JI, AIRAKSINEN KE, MUSTONEN JN et al: Thyroid and myocardial function after replacement of carbamazepine by oxcarbazepine. Epilepsia (1995) 36:810–816.
   PubMed Web of Science ®Google Scholar
• ISOJARVI JI, PAKARINEN AJ, RAUTIO A, PELKONEN 0, MYLLYLA VV: Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia (1994) 35:1217–1220.
   PubMed Web of Science ®Google Scholar
• ISOJARVI JIT, PAKARINEN AJ, RAUTIO A, PELKONEN 0, MYLLYLA VV: Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Pharmokinetics and Disposition (1994):461–464.
   Google Scholar
• KLOSTERSKOV JENSEN P, SAANO V, HARING P, SVENSTRUP B, MENGE GP: Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia (1992) 33:1149–1152.
   PubMed Web of Science ®Google Scholar
• SONNEN AEH: Oxcarbazepine and oral contraceptives. Acta Neurol. Scand. (1990) 82\(Suppl. 133):37.
   Google Scholar
• AUGUSTEIJN R, VAN PARYS JAP: Oxcarbazepine (Trileptal, OXC) - dose-concentration relationship in patients with epilepsy. Acta Neurol. Scand. (1990) 82\(Suppl. 133)37.
   Google Scholar
• DICKINSON RG, HOOPER WD, DUNSTAN PR, EADIE MJ: First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur. J. Pharmacol. (1989) 37:69–74.
   Web of Science ®Google Scholar
• LLOYD P, FLESCH G, DIETERLE W: Clinical pharma-cology and pharmacokinetics of oxcarbazepine. Epilepsia (1994) 35:S10–13.
   PubMed Web of Science ®Google Scholar
• KRISTENSEN 0, KLITGAARD NA, JONSSON B, SINDRUP S: Pharmacokinetics of 10-0H-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol. Scand. (1983) 68:145–150.
   PubMed Web of Science ®Google Scholar
• ROUAN MC, LECAILLON JB, GODBILLON J et al: The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur. J. Clin. Pharmacol. (1994) 47:161–167.
   PubMed Web of Science ®Google Scholar
• VAN HEININGEN PN, EVE MD, OOSTERHUIS B et al.: The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Gun. Pharmacol. Ther. (1991) 50:410–419.
   PubMed Web of Science ®Google Scholar
• HOUTKOOPER MA, LAMMERTSMA A, MEYER JWA et al.: Oxcarbazepine (GP 47680) - a possible alternative to carbamazepine? Epilepsia (1987) 28:693–698.
   Google Scholar
• SCHMUTZ M, BRUGGER F, GENTSCH C, MCLEAN MJ, OLPE HR: Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia (1994) 35 (Suppl. 5):547–S50.
   Google Scholar
• WAMIL AW, PORTET CH, JENSEN PK, SCHMUTZ M, MCLEAN MJ: Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture. Epilepsia (1991) 32:65–66.
   Google Scholar
• MCLEAN MJ, SCHMUTZ M, WAMIL AW et al.: Oxcarbazepine: mechanisms of action. Epilepsia (1994) 35\(Suppl. 3):S5–S9.
   Google Scholar
• •Good overview of the cellular mechanisms of action of oxcarbazepine.
   Google Scholar
• STEFANI A, PISANI A, DE MURTAS M et al.: Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia (1995) 36:997–1002.
   Google Scholar
• CALABRESI P, DE MURTAS M, STEFANI A et al: Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostri-atal synaptic transmission. Epilepsia (1995) 36:990–996.
   Google Scholar
• WALDMEIER PC, BAUMANN PA, WICKI P et al.: Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology (1995) 45:1907–1913.
   PubMed Web of Science ®Google Scholar
• WAMIL AW, SCHMUTZ M, PORTET C, FELDMANN KF, MCLEAN MJ: Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur. J. Pharmacol. (1994) 271:301–308.
   PubMed Web of Science ®Google Scholar
• REINIKAINEN KJ, KERANEN T, HALONEN T, KOMULAINEN H, RIEKKINEN PJ: Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res. (1987) 1:284–289.
   PubMed Web of Science ®Google Scholar
• DAM M, EKBERG R, LOYNING Y, WALTIMO 0, JAKOBSENK: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. (1989) 3:70–76.
   PubMed Web of Science ®Google Scholar
• CHRISTE W, KRAMER G, VIGONIUS U et al.: A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. (1997) 26:451–460.
   PubMed Web of Science ®Google Scholar
• BILL PA, VIGONIUS U, POHLMANN H et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. (1997) 27:195–204.
   PubMed Web of Science ®Google Scholar
• GUERREIRO MM, VIGONIUS U, POHLMANN H et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. (1997) 27:205–213.
   PubMed Web of Science ®Google Scholar
• PLEDGER GW, KRAMER LD: Clinical trials of investiga-tional antiepileptic drugs: monotherapy designs. Epilepsia (1991) 32:716–721.
   PubMed Web of Science ®Google Scholar
• FISHER RS, ESKOLA J, BLUM D et al.: Open-label, pilot study of oxcarbazepine for inpatients under evalua-tion for epilepsy surgery. Drug DevRes. (1996) 38:43–49.
   Web of Science ®Google Scholar
• SCHACHTER SC, VAZQUEZ B, FISHER RS et al.: Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology (1999) 52:732–737.
   PubMed Web of Science ®Google Scholar
• •First placebo-controlled study of oxcarbazepine.
   Google Scholar
• SACHDEO R, BEYDOUN A, SCHACHTER S, VAZQUEZ B: Safety and efficacy of oxcarbazepine monotherapy. Neurology (1998) 50:A200.
   Web of Science ®Google Scholar
• BULAU P, STOLL KD, FROSCHER W: Oxcarbazepine versus carbamazepine. In: Advances in Epileptology. XVIth Epilepsy International Symposium Wolf P, Dam M, Janz D, Dreifuss FE, (Eds.), New York: Raven Press, USA (1987):531–536.
   Google Scholar
• VAN PARYS JAP, MEINARDI H: Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res. (1994) 19:79–85.
   PubMed Web of Science ®Google Scholar
• DAM M: Practical aspects of oxcarbazepine treatment. Epilepsia (1994) 35:S23–25.
   PubMed Web of Science ®Google Scholar
• BORUSIAK P, KORN-MERKER E, HOLERT N, BOENIGK HE: Oxcarbazepine treatment of childhood epilepsy: a survey of 46 children and adolescents. J. Epilepsy (1998) 11:355–360.
   Google Scholar
• GAILY E, GRANSTROM M-L, LIUKKONEN E: Oxcarbazepine in the treatment of early childhood epilepsy. J. Child. Neurol. (1997) 12:496–498.
   PubMed Web of Science ®Google Scholar
• FRIIS ML, KRISTENSEN 0, BOAS J et al. Therapeutic experiences with 947 epileptic out-patients in
   Google Scholar
• JENSEN NO.:Oxcarbazepine in patients hypersensitiveto carbamazepine. 16th Epilepsy International Congress. Hamburg, Germany (1983).
   Google Scholar
• BERAN RG: Cross-reactive skin eruption with bothcarbamazepine and oxcarbazepine. Epilepsia (1993) 34:163–165.
   PubMed Web of Science ®Google Scholar
• TROOST RJ, VAN PARYS JA, HOOIJKAAS H et al: Allergyto carbamazepine: parallel in vivo and in vitro detection. Epilepsia (1996) 37:1093–1099.
   PubMed Web of Science ®Google Scholar
• CURRAN HV, JAVA R: Memory and psychomotor effectsof oxcarbazepine in healthy human volunteers. Eur. J. Clin. Pharmacol. (1993) 44:529–533.
   PubMed Web of Science ®Google Scholar
• SABERS A, MOLLER A, DAM M et al.: Cognitive functionand anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand. (1995) 92:19–27.
   PubMed Web of Science ®Google Scholar
• AIKIA M, KALVIAINEN R, SIVENIUS J, HALONEN T,RIEKKINEN PJ: Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res. (1992) 11:199–203.
   PubMed Web of Science ®Google Scholar
• CIBA-GEIGY LTD: International product information,Basel: Ciba, 1996.
   Google Scholar
• STEINHOFF BJ, STOLL K-D, STODIECK SRG, PAULUS W:Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res. (1992) 11:67–70.
   PubMed Web of Science ®Google Scholar
• VAN AMELSVOORT T, BAKSHI R, DEVAUX CB, SCHWABES: Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia (1994) 35 :181–188.
   PubMed Web of Science ®Google Scholar
• PENDLEBURY SC, MOSES DK, EADIE MJ: Hyponatraemiaduring oxcarbazepine therapy. Hum. Toxicol. (1989) 8:337–344.
   PubMedGoogle Scholar
• NIELSEN OA, JOHANNESSEN AC, BARDRUM B: Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res. (1988) 2:269–271.
   PubMed Web of Science ®Google Scholar
• PIENIMAKI P, LAMPELA E, HAKKOLA J etal: Pharmacoki-netics of oxcarbazepine and carbamazepine in human placenta. Epilepsia (1997) 38:309–316.
   PubMed Web of Science ®Google Scholar
• GRANT SM, FAULDS D: Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs (1992) 43:873–888.
   Google Scholar
• REMILLARD G: Oxcarbazepine and intractable trigeminal neuralgia. Epilepsia (1994) 35:S28–S29.
   Web of Science ®Google Scholar
• ZAKRZEWSKA JM, PATSALOS PN: Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J. Neurol. Neurosurg. Psychiatry (1989) 52:472-476. Steven C Schachter
   Google Scholar